A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
André, F., Kaufman, B., Juric, D., Ciruelos, E., Iwata, H., Mayer, I.A., Conte, P., Rugo, H.S., Loibl, S., Rubovszky, G., Tesch, H., Inoue, K., Lu, Y-S., Ryvo, L., Longin, A-S., Mills, D., Wilke, C.,Volume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw365.90
Date:
October, 2016
File:
PDF, 47 KB
english, 2016
File converter
More search results
More benefits 
